Lotamilast

Research use only, not for human use.

Lotamilast (RVT 501, E6005) is apotent, selective PDE4 inhibitor with IC50 of 2.8 nM, suppresses the production of various cytokines from human lymphocytes and monocytes with IC50 of 0.49-3.1 nM.

Lotamilast (RVT 501, E6005) is apotent, selective PDE4 inhibitor with IC50 of 2.8 nM, suppresses the production of various cytokines from human lymphocytes and monocytes with IC50 of 0.49-3.1 nM; produces an immediate antipruritic effect as well as an anti-inflammatory effect with reduced expression of cytokines/adhesion molecules in mice after topical application; ameliorates the appearance of atopic dermatitis-like skin lesions in AD models.Dermatitis Phase 2 Clinical

RVT 501;E6005

Angiogenesis

PDE

PDE4;PDE-4

Inflammation/Immunology

Dermatitis

947620-48-6

472.50

C26H24N4O5

>98% (HPLC)

（ < 1 mg/ml refers to the product slightly soluble or insoluble )

O=C(OC)C1=CC=C(C(NC2=CC=CC(C3=C4C=C(OC)C(OC)=CC4=NC(NC)=N3)=C2)=O)C=C1

methyl 4-({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}carbamoyl)benzoate

(-20℃)

With Ice Pack

≥ 2 years